UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
UNITY Biotechnology [NASDAQ: UBX] has appointed Alicia Tozier, MBA, as Chief Strategy Officer. With 20 years of experience in pharma and medical devices, including a decade in retinal diseases, Tozier will develop and implement corporate and product strategies. Her expertise in ophthalmology product planning and commercial strategy is expected to be important for advancing UBX1325, UNITY's lead program for diabetic macular edema (DME).
Tozier's impressive track record includes leading 18 launches across 8 therapeutic areas in 70 global markets. She previously held senior roles at Outlook Therapeutics, Genentech Pharmaceuticals, Astellas Pharmaceuticals, and Baxter Healthcare. Her experience in scaling cross-functional teams and executing go-to-market strategies, particularly in ophthalmology, is seen as valuable for UNITY's strategic vision and operational excellence.
UNITY Biotechnology [NASDAQ: UBX] ha nominato Alicia Tozier, MBA, come Chief Strategy Officer. Con 20 anni di esperienza nel settore farmaceutico e dei dispositivi medici, compresi dieci anni nelle malattie retiniche, Tozier svilupperà e implementerà strategie aziendali e di prodotto. La sua esperienza nella pianificazione dei prodotti oftalmologici e nella strategia commerciale è ritenuta fondamentale per far progredire UBX1325, il principale programma di UNITY per il edema maculare diabetico (DME).
Il brillante curriculum di Tozier comprende la guida di 18 lanci in 8 aree terapeutiche in 70 mercati globali. In precedenza ha ricoperto ruoli dirigenziali presso Outlook Therapeutics, Genentech Pharmaceuticals, Astellas Pharmaceuticals e Baxter Healthcare. La sua esperienza nel potenziare team interfunzionali ed eseguire strategie di go-to-market, in particolare in oftalmologia, è vista come un valore aggiunto per la visione strategica e l'eccellenza operativa di UNITY.
UNITY Biotechnology [NASDAQ: UBX] ha nombrado a Alicia Tozier, MBA, como Directora de Estrategia. Con 20 años de experiencia en farmacéutica y dispositivos médicos, incluyendo una década en enfermedades retinianas, Tozier desarrollará e implementará estrategias corporativas y de producto. Se espera que su experiencia en la planificación de productos oftalmológicos y en la estrategia comercial sea importante para avanzar en UBX1325, el programa principal de UNITY para el edema macular diabético (DME).
El impresionante historial de Tozier incluye liderar 18 lanzamientos en 8 áreas terapéuticas en 70 mercados globales. Anteriormente ocupó cargos de alto nivel en Outlook Therapeutics, Genentech Pharmaceuticals, Astellas Pharmaceuticals y Baxter Healthcare. Su experiencia en escalar equipos multifuncionales y ejecutar estrategias de comercialización, especialmente en oftalmología, se considera valiosa para la visión estratégica y la excelencia operativa de UNITY.
UNITY Biotechnology [NASDAQ: UBX]는 앨리시아 토지어, MBA를 전략 최고 책임자(Chief Strategy Officer)로 임명했습니다. 그녀는 제약 및 의료 기기 분야에서 20년의 경력을 가지고 있으며, 그 중 10년은 망막 질환에 집중해왔습니다. 토지어는 기업 및 제품 전략을 개발하고 구현할 것입니다. 그녀의 안과 제품 계획 및 상업 전략에 대한 전문성은 UNITY의 주요 프로그램인 당뇨병성 황반부종(DME)의 발전에 중요한 역할을 할 것으로 예상됩니다.
토지어는 70개 글로벌 시장에서 8개 치료 분야에 걸쳐 18개의 런칭을 이끌어낸 인상적인 경력을 가지고 있습니다. 그녀는 Outlook Therapeutics, Genentech Pharmaceuticals, Astellas Pharmaceuticals 및 Baxter Healthcare에서 고위직을 역임했습니다. 특히 안과 분야에서 다기능 팀을 확장하고 시장 진입 전략을 실행한 경험은 UNITY의 전략적 비전과 운영 우수성을 위한 중요한 자산으로 평가되고 있습니다.
UNITY Biotechnology [NASDAQ: UBX] a nommé Alicia Tozier, MBA, au poste de Directrice de la Stratégie. Forte de 20 ans d'expérience dans le secteur pharmaceutique et des dispositifs médicaux, dont une dizaine d'années consacrées aux maladies rétiniennes, Tozier développera et mettra en œuvre des stratégies d'entreprise et de produit. Son expertise en planification de produits ophtalmologiques et en stratégie commerciale est jugée cruciale pour faire progresser UBX1325, le programme phare de UNITY pour l'œdème maculaire diabétique (DME).
Le parcours impressionnant de Tozier comprend la direction de 18 lancements dans 8 domaines thérapeutiques sur 70 marchés mondiaux. Elle a précédemment occupé des postes de direction chez Outlook Therapeutics, Genentech Pharmaceuticals, Astellas Pharmaceuticals et Baxter Healthcare. Son expérience en matière de développement d'équipes interfonctionnelles et d'exécution de stratégies de mise sur le marché, particulièrement en ophtalmologie, est perçue comme précieuse pour la vision stratégique et l'excellence opérationnelle de UNITY.
UNITY Biotechnology [NASDAQ: UBX] hat Alicia Tozier, MBA, zur Chief Strategy Officer ernannt. Mit 20 Jahren Erfahrung in der Pharma- und Medizintechnikbranche, davon ein Jahrzehnt im Bereich der retinalen Erkrankungen, wird Tozier Unternehmens- und Produktstrategien entwickeln und umsetzen. Ihre Expertise in der Produktplanung für Augenheilkunde und der kommerziellen Strategie wird als wichtig für den Fortschritt von UBX1325, dem Hauptprogramm von UNITY für diabetisches Makulaödem (DME), angesehen.
Toziers beeindruckende Erfolgsbilanz umfasst die Leitung von 18 Produkteinführungen in 8 therapeutischen Bereichen in 70 globalen Märkten. Zuvor bekleidete sie leitende Positionen bei Outlook Therapeutics, Genentech Pharmaceuticals, Astellas Pharmaceuticals und Baxter Healthcare. Ihre Erfahrung in der Skalierung von interdisziplinären Teams und der Umsetzung von Markteinführungsstrategien, insbesondere in der Augenheilkunde, wird als wertvoll für die strategische Vision und operationale Exzellenz von UNITY betrachtet.
- Appointment of experienced Chief Strategy Officer with 20 years of industry expertise
- New CSO has led 18 product launches across 8 therapeutic areas in 70 global markets
- Potential to strengthen UBX1325 development and market strategy for diabetic macular edema
- Addition of expertise in ophthalmology product planning and commercial strategy
- None.
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company’s corporate and product strategies.
“Alicia’s impressive experience in ophthalmology product planning, commercial strategy, and scaling cross-functional teams will be instrumental in fortifying our strategies and capitalizing on the significant opportunity of UBX1325 to transform the treatment landscape for diabetic macular edema (DME),” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “She has an outstanding track record of rapidly building and executing go-to-market strategies, including a record-breaking product launch in the ophthalmology space, which will be invaluable as we continue to advance our lead program through late-stage clinical development. I am confident that Alicia will help drive our strategic vision with operational excellence, ensuring we remain at the forefront of innovation in chronic and inflammatory diseases associated with aging."
Ms. Tozier brings 20 years of experience working in the pharma and medical device industry, including over a decade in the retinal disease space. To date, she has led 18 launches across eight therapeutic areas spanning 70 markets globally, while operationalizing numerous firsts at Genentech Pharmaceuticals (GNE), Astellas Pharmaceuticals and Baxter Healthcare. Prior to joining UNITY, Ms. Tozier was senior vice president at Outlook Therapeutics where she drove organizational activation and go to market, scaling multiple global functions for the pre-commercial biopharmaceutical company’s global entry. Previously, she was head of ophthalmology at GNE with US oversight for market access, marketing and specialty sales where she mobilized the company’s inaugural entry into the surgical market with PDS. In addition, she scaled a multi-functional faricimab team to achieve the fastest growing launch in anti-VEGF history, representing a top growth driver for GNE. Ms. Tozier also served as global leader for Astellas Pharmaceuticals and Baxter Healthcare building global new product planning strategies and organizational capabilities for novel paradigm shifting regenerative medicine and digital therapeutics, launching four platforms across 70+ markets. Ms. Tozier is a Stanford Graduate Business School Alumni, recently graduating from the Executive Leadership Program, and earned her MBA at Colorado State University and BA from the University of California Santa Barbara.
“It is exciting to see the advances that UNITY has made,” stated Ms. Tozier. “I believe the company is well positioned as it pivots into a late-stage clinical development organization. I’m delighted to join the leadership team to help shape the company’s strategic direction and broad potential of the product platform. With impressive clinical data to date, UBX1325 has a significant opportunity to bring a novel therapeutic to DME patients. I look forward to contributing to the success of this mission.”
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME and other ophthalmologic diseases, the expected timing of enrollment and results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks of delay or disruption of enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the Securities and Exchange on May 14, 2024, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.
Media Contact
Inizio Evoke Comms
Katherine Smith
Katherine.Smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
Who is the new Chief Strategy Officer of UNITY Biotechnology (UBX)?
What is UNITY Biotechnology's (UBX) lead program?
What is Alicia Tozier's experience in the pharmaceutical industry?
How might Alicia Tozier's appointment impact UNITY Biotechnology (UBX)?
